Novartis' Kelly Lindert Joins Tokai
This article was originally published in Scrip
Executive Summary
Tokai Pharmaceuticals Inc., a company focused on prostate cancer and other hormonal diseases, has appointed Kelly A. Lindert executive vice president and head of development. Lindert joins the company from Novartis AG where she spent eight years in various roles, most recently as global head of development for the company's influenza vaccines program.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.